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ABSTRACT. The production of hydrogel microspheres (MS) for cell immobilization, 
maintaining the favorable properties of alginate gels but presenting enhanced performance in 
terms of in vivo durability and physical properties, is desirable to extend the therapeutic potential 
of cell transplantation. A novel type of hydrogel MS was produced by straightforward 
functionalization of sodium alginate (Na-alg) with heterocheletic poly(ethylene glycol) (PEG) 
derivatives equipped with either end thiol or 1,2-dithiolane moieties. Activation of the hydroxyl 
moieties of the alginate backbone in the form of imidazolide intermediate allowed for fast 
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conjugation to PEG oligomers through a covalent carbamate linkage. Evaluation of the modified 
alginates for the preparation of MS combining fast ionic gelation ability of the alginate 
carboxylate groups and slow covalent crosslinking provided by the PEG-end functionalities 
highlighted the influence of the chemical composition of the PEG-grafting units on the physical 
characteristics of the MS. The mechanical properties of the MS (resistance and shape recovery) 
and durability of PEG-grafted alginates in physiological environment can be adjusted by varying 
the nature of the end functionalities and the length of the PEG chains. In vitro cell 
microencapsulation studies and preliminary in vivo assessment suggested the potential of these 
hydrogels for cell transplantation applications. 
INTRODUCTION 
Progress in therapies relying on the allo- or xenotransplantation of immobilized cells and tissue 
strongly depends on the quality of the immobilizing material. Currently, the translation of related 
therapies to the clinics, for example to treat end-stage organ failure and end-stage diseases such 
as cancer, diabetes mellitus and acute liver failure,1,2 is not at least hindered by the lack of 
materials having the perfect properties. Hydrogels prepared from the biopolymer sodium alginate 
(Na-alg) or derivatives of it have been reported in abundant papers as particularly advantageous 
because they fulfill general requirements such as the spontaneous formations of hydrogels in the 
presence of divalent cations (e.g. Ca2+, Ba2+) under mild conditions of temperature and pH, and 
high biocompatibility.3-6 Maintaining these advantages but overcoming several drawbacks, 
including the lack of in vivo mechanical resistance and stability, and defects in permselectivity,7,8 
are the focus of current research. There are additional limitations caused by the dimension of the 
targeted final application. This calls in particular for therapies which intend the transplantation of 
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allo- or xenogeneic cells immobilized in microspheres (MS) in order to allow for mini-invasive 
surgery.9,10 The stabilization of alginate gel beads by coating the MS with polycations such as 
(poly(L-lysine), poly(L-ornithine) and poly(L-guanidine) was investigated, but resulted in worse 
cell graft function in vivo.11 Another strategy to improve the performance of alginate MS relies 
on the combination with other polymers such as poly(ethylene glycol) (PEG). Following this 
approach, the combination of fast ionotropic gelation of Na-alg with slow covalent crosslinking 
provided by PEG derivatives, either covalently linked to the alginate backbone or in the form of 
an interpenetrating network, was proposed. This included two-component MS, composed of Ca-
alg and covalently cross-linked vinyl sulfone-terminated multiarm PEG12-14 and one-component 
MS, prepared from Na-alg derivatives grafted with heterobifunctional derivatives either on the 
carboxyl groups15 or the hydroxyl moieties.16 Despite the improved mechanical properties and 
permselectivity compared to pure Ca-alg MS, in particular the latter lacked of in vivo durability, 
probably due to the lability of the ester linkage which was introduced as grafting unit. This asked 
for the development of alternative grafting strategies. A panel of crosslinking strategies based on 
click reactions have been reported in the literature for the preparation of synthetic-based and 
biopolymer-based hydrogels to mimic the physiological cellular microenvironment and deliver 
therapeutic proteins and peptides promoting cell viability and functionality.17-19 However, these 
techniques, mainly developed on PEG and hyaluronic acid derivatives, are not favorable for the 
production of hydrogel MS intended for cell therapies.  
The present study intends to enlarge the variety of hybrid alginate materials suitable for cell 
immobilization in spherical 3D hydrogels, in particular regarding in vivo durability. Another key 
aspect concerns the development of a robust synthetic protocol for the preparation of Na-alg 
derivatives grafted with heterobifunctional PEG oligomers, amenable to up-scaled production. 
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First, we produced heterocheletic PEG derivatives presenting ?-amine and ?-thiol functionalities 
to allow grafting to the alginate backbone and covalent crosslinking during MS formation, 
respectively. Second, a straightforward procedure was developed for the preparation of PEG-
grafted Na-alg derivatives using a carbamate linkage to functionalize the hydroxyl moieties of 
Na-alg. The resulting hydrogels, produced in a one-step process, were characterized in terms of 
chemical composition and mechanical properties. Finally, the MS were evaluated both in vitro   
and in vivo, for their in vitro cytocompatibility using mice insulin producing cell lines and for 
their in vivo stability using a mice model. 
EXPERIMENTAL SECTION 
Materials and Methods. Na-alg Kelton HV (lot no. 61650A, [Ș] = 813 mL gí in 0.1 M NaCl, 
T = 25 °C, G/M = 0.6) was obtained from Kelco (San Diego, USA, CA). Linear PEG (molar 
mass MM= 1000 g.mol-1 and 2000 g.mol-1, degree of polymerization DP= 22 and 44, designated 
as PEG-a and PEG-b) were obtained from Sigma (Buchs, Switzerland). Other commercial 
reagents (Fluka, Sigma, Switzerland; TCI Europe, Zwijndrecht, Belgium) were used without 
further purification. Unless special mention, all reactions were performed under argon 
atmosphere (1 atm). Anhydrous solvents were obtained by filtration (Puresolv MD 5, Innovative 
Technology, Oldham, UK). Glassware was dried for 12 h in an oven (T > 100 °C) or under 
vacuum with a heat gun (T > 200 °C). Reactions were monitored by TLC (Merck silica gel 
60F254 plates, Merck, Darmstadt, Germany). Detection was performed by UV light, KMnO4, 
Ninhydrin or I2. Purifications were performed by flash chromatography on silica gel (Merck N° 
9385 silica gel 60, 240-400 mesh). NMR spectra were recorded on Bruker Avance III-400, 
Bruker Avance-400 or Bruker DRX-400 spectrometers at room temperature (rt) (400 MHz) 
(Bruker, Billerica, MA, USA). 1H frequency is at 400.13 MHz, 13C frequency is at 100.62 MHz. 
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Chemical shifts are expressed in parts per million (ppm) and coupling constants (J) in hertz (Hz). 
Solvents used for NMR spectroscopy were deuterated chloroform (CDCl3, Acros), deuterated 
methanol (CD3OD, Acros) and deuterated water (D2O). Mass spectra were obtained on a Nermag 
R-10-10C spectrometer with chemical ionization (NH3) and mode m/z (amu) [% relative base 
peak (100%)] (Nermag, Santa Clara, CA, USA). IR spectra were recorded on a Jasco FT/IR-
4100 spectrometer outfitted with a PIKE technology MIRacleTM ATR accessory as neat films 
compressed onto a Zinc Selenide window. The spectra are reported in cm-1. Mass spectra were 
obtained by using a Waters ACQUITY H-class UPLC/MS ACQ-SQD by electron ionization (EI 
positive and negative) or a Finnigan TSQ7000 by electrospray ionization (ESI+). The accurate 
masses were measured by ESI-TOF using a QTOF Ultima from Waters. 
Formation of one-component microspheres. Solutions of Na-Alg-PEG polymers were 
prepared according to the following formulation: Na-alg-PEG was dissolved in a solution of 0.4 
% NaCl in 100 mM MOPS buffer, pH 7.4 at the desired concentration. After complete 
dissolution, the polymer solution was directly extruded into a gelation bath (100 mM CaCl2 in 
100 mM MOPS buffer, pH 7.4) containing tween 80 (1/10 000). MS were produced employing a 
coaxial air-flow droplet generator (Encapsulator B-395 Pro, Büchi Labortechnik AG, Flawil, 
Switzerland). The MS were collected by filtration, washed twice with CaCl2 stock solution, and 
finally stored in this solution at 4 °C, or in cell culture medium in case of cell 
microencapsulation. 
Physical characterization of microspheres. The average diameter was measured on an 
Olympus AX70 microscope equipped with an Olympus DP70 color digital camera. The 
mechanical resistance to 90% compression of the initial MS diameter was analyzed using a 
texture analyzer (TA-XT2i, software Texture Exponent 32, Stable Micro Systems, Godalming, 
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UK) equipped with a force transducer (1 mN resolution). A single MS was placed below the 
probe, for which a constant speed was set as 0.5 mm s-1. Thirty MS of each batch were included 
in the analysis.  
Microencapsulation of MIN6 cells. MIN6 cells were cultured in Dulbecco Modified Eagle’s 
Medium (DMEM) supplemented with 1mM Na-3\UXYDWH  0 ȕ-mercaptoethanol, 15% 
decomplemented Fetal Calf Serum, 25 mM glucose, Penicillin and streptomycin (DMEM 
complete medium). 10x106 MIN6 cells were gently mixed in 1 ml of Na-alg-PEG solution. MS 
were produced using the same procedure as described above for the formation of one-component 
MS. Encapsulated and free MIN6 cells were cultured up to 15 days in DMEM complete medium 
and were analyzed for viability and functionality by FDA/PI staining and glucose-stimulated 
insulin release assay, as previously described.20  
Transplantation of MS in mice. Animal research was performed according to the Geneva 
cantonal veterinary authorities (license GE/34/13). 1ml of empty MS was transferred into the 
peritoneum of anesthetized immunocompetent C57/BL6 mice through a small abdominal 
incision. After 30 days, mice were sacrificed for a macroscopic evaluation of fibrotic reactions in 
the peritoneum. 
Synthesis protocols. The designation of the compounds refers to the chemical structures 
presented in Scheme 1 and Scheme 2. 
Preparation of compound 2. To a solution of 3-mercaptopropionic acid (1 equiv, 94.2 mmol, 
10 g) in H2O: THF (1:1, 180 mL) were added Boc2O (1.2 equiv, 113.04 mmol, 24.7 g) and Et3N 
(2 equiv, 188.4 mmol, 19.07 g, 25.43 mL) and the reaction mixture was stirred for 12 h at rt. 
THF was evaporated under vacuo and 1 M HCl (50 mL) was added. The product was extracted 
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with DCM (3 x 100 mL). The combined organic layers were dried (MgSO4) and concentrated in 
vacuo. The product was purified by FCC on silica gel (PE/EtOAc 8:1) to afford 2 as a 
transparent oil (43.3 mmol, 8.92 g, 46 %). 1H-NMR, 13C NMR,IR (neat), and HRMS-ESI data 
(supporting information S2). 
Preparation of compound 3a. EDCI (3 equiv, 5.64 mmol, 875.6 mg) and Et3N (3 equiv, 5.64 
mmol, 570.7 mg) were added to a solution of 1a (1 equiv, 1.88 mmol, 2 g) and 2 (2 equiv, 3.77 
mmol, 778 mg) in DCM (20 mL). The reaction mixture was stirred 24 h at rt and subsequently 
washed with sat. NH4Cl solution (2 x 20 mL) and with sat. NaHCO3 solution (2 x 20 mL). The 
organic phase was dried (MgSO4) and concentrated in vacuo. The product was purified by FCC 
on silica gel (DCM/MeOH 20:1 to 10:1) to afford 3a as a yellowish oil (1.74 mmol, 1.94 g, 93 
%). 1H-NMR, 13C NMR, IR (neat), and HRMS-ESI data (supporting information S3). Compound 
3b was prepared according to the same protocol. 
Preparation of PEG-a I. To a solution of compound 3a (1 equiv, 1.46 mmol, 1.5 g) in toluene 
(7.5 mL), PPh3 (1.8 equiv, 2.70 mmol, 708 mg) was added and the mixture was stirred for 30 
min at rt. Then, 1M HCl (19.7 mL) was added and stirring continued for 48 h at rt. The two 
phases were separated and the organic phase was washed with 1 M HCl (2 x 20 mL). The 
combined aqueous layers were washed with DCM (10 mL) before being concentrated in vacuo. 
After co-evaporation with toluene (3 x 10 mL), compound PEG-a I was obtained as a yellowish 
amorphous solid (3.37 µmol, 3.32 g, 95 %). 1H-NMR, 13C NMR, IR (neat) and HRMS-ESI data 
(supporting information S4). Polymer PEG-b I was prepared according to the same protocol. 
Preparation of compound 4. EDCI (1.5 equiv, 72 mmol, 11.17 g) and NHS (1.5 equiv, 72 
mmol, 8.36 g) were added to a solution of lipoïc acid (1 equiv, 48 mmol, 10 g) in DMF (30 mL). 
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The reaction mixture was stirred 12 h at rt and concentrated in vacuo. The crude product was 
dissolved in DCM and washed three times with H2O and brine. The organic phase was dried 
(MgSO4) and concentrated in vacuo. The product was purified by FCC on silica gel (EtOAc/PE 
1:1) to afford 4 as a yellow solid (22.42 mmol, 6.79 g, 46 %). 1H-NMR, 13C NMR, IR (neat), and 
HRMS-ESI data (supporting information S5).  
Preparation of compound 5a. To a solution of compounds 1a (1 equiv, 4.72 mmol, 5 g) and 4 
(2 equiv, 9.44 mmol, 2.86 g) in DMF (35 mL), Et3N (1 equiv,4.72 mmol, 477 mg) was added. 
The reaction mixture was stirred for 48 h at rt before evaporating the solvent in vacuo. The crude 
product was dissolved in DCM (100 mL) and washed with sat. NH4Cl (2 x 40 mL). The organic 
phase was dried (MgSO4) and concentrated in vacuo. The product was purified by FCC on silica 
gel (DCM/MeOH 17:1) to afford 5a as a yellowish amorphous solid (3.71 mmol, 4.63 g, 78 %). 
1H-NMR, 13C NMR, IR (neat) and HRMS-ESI data (supporting information S6). Compound 5b 
was prepared according to the same protocol. 
Preparation of PEG-a II. Compound 5a (1 equiv, 866 µmol, 1 g) was dissolved in THF (5 
mL). LiAlH4 (2 equiv, 1.73 mmol, 66 mg) was added portion-wise and the reaction was stirred 
for 40 min at rt. The reaction was quenched by slow addition of EtOAc (2 mL), then H2O (20 
ML) and the product was extracted with DCM (3 x 30 mL). The combined organic layers were 
dried (MgSO4) and concentrated in vacuo to afford PEG-a II as a white amorphous solid (791 
µmol, 895 mg, 91 %). IR (neat) and HRMS-ESI data (supporting information S7). Polymer 
PEG-b II was prepared according to the same protocol. 
Preparation of TBA-alg. Na-alg (Kelton HV, 1.0 g) was suspended in EtOH (50 mL) and the 
solution was cooled to 0 °C. Formic acid (20 % aqueous solution, 50 mL) was added, and the 
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mixture was stirred for 12 h at 0 °C. The resulting alginic acid powder was separated by vacuum 
filtration, washed with a mixture of EtOH/H20 1:1 (3 x 50 mL) and then acetone (3 x 50 mL). 
The resulting solid was further dried for 15  min under vacuum at 40 °C, and dispersed in water 
(50 mL). TBAOH (40 % in water) was added dropwise until reaching pH 7. The solution was 
directly freeze-dried to afford TBA-Alg as a white solid. 
General protocol for the functionalization of TBA-alg. TBA-alg (1 equiv, 0.239 mmol, 100 
mg) was dissolved in DMSO (20 mL) and the solution was stirred for 12 h to ensure 
homogeneity. CDI (1 equiv, 0.239 mmol, 38.7 mg) previously dissolved in a minimum volume 
of DMSO was added, and the reaction mixture was stirred at rt for 30 min. To enhance 
precipitation of the imidazolide-alginate intermediate, acetone (40 mL) was added. The resulting 
precipitate was filtered and washed with acetone (3 x 10 mL). The solid was further dried for 15 
min under vacuum at 40 °C, and transferred to a round-bottom flask. Distilled water was added 
(10 mL), and the mixture was stirred until complete dissolution. Heterobifunctional PEG 
derivative (0.2 equiv, 47.9 µmol) previously dissolved in a minimum volume of water was 
added. The solution was stirred at rt for 2 h. The reaction was quenched by addition of 0.05M 
NaOH solution until reaching pH 11. The solution was directly transferred into a dialysis 
membrane and dialyzed against distilled water. The first day, the water was changed once. A 
second water change was performed with prior addition of  TCEP (0.1 M, 1 mL) in the dialysis 
tube. The dialysis was continued for 2 more days, adding TCEP (0.1 M, 1 mL) one more time to 
the dialysis tube, and followed by dialysis against distilled water the second day (changing water 
3 times that day). The last day the dialysis was continued against water, with the addition of 
NaHCO3 (180 mg in 9 L distilled water) in the dialysis bucket, to reach pH 7. The solution was 
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filtered (70 µm and 0.22 µm) and freeze-dried to obtain the PEG-grafted alginates as white 
solids. 
RESULTS AND DISCUSSION 
Preparation of heterobifunctional PEG derivatives. The development of PEG-grafted alg 
materials for cell microencapsulation applications requires access to a variety of heterocheletic 
PEG oligomers. Scheme 1 presents details of the synthesis routes to obtain the heterocheletic 
derivatives. Following our previous reports on the production of azido- and amino-silanized PEG 
molecules,21,22 straightforward synthetic pathways were developed to produce thiol- and 1,2-
dithiolane-functionalized PEG derivatives. Starting from the linear PEG-a or PEG-b, the key 
intermediates Į-amino-Ȧ-azido PEG 1a and 1b were obtained in good overall yields (3 steps) 
according to a previously established protocol.21  PEG-a I and PEG-b I oligomers were 
obtained by a coupling reaction with protected 3-mercaptopropanoïc acid (2), followed by 
simultaneous reduction of the azido group and deprotection of the thiol functionality. 
Alternatively, conjugation to activated lipoic acid followed by reduction in the presence of 
LiAlH4 delivered PEG-a II and PEG-b II as mixtures of opened (reduced) and closed (oxidized) 
forms of the dithiolane functionality. The end thiol functionalities in PEG-a I and PEG-b I 
derivatives are expected to produce disulfide bridge crosslinking during MS formation. The 
terminal 1,2-dithiolanes in PEG-a II and PEG-b II  compounds were introduced due to their fast 
and tunable disulfide exchange properties, which can produce disulfide clusters through multiple 
crosslinking interactions.23,24 
Scheme 1. Synthesis of heterocheletic PEG derivatives. (for a: n=22, for b: n=44) 
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Functionalization of Na-alg with PEG derivatives. The alg backbone presents a distribution of 
carboxyl and hydroxyl functionalities available for chemical functionalization. The chemical 
modification of the carboxyl groups can be performed by simple esterification25 or formation of 
amide linkage26-29 using carbodiimide chemistry or activation with N-hydroxysuccinimide. 
However, this technique reduces the number of carboxyl groups for ionic cross-linking. 
Hydroxyl groups at C2 and C3 positions of the uronic units of alginate can be oxidized30 for 
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further derivatization by reductive amination.31 The oxidation step increases the degradation rate 
of the resulting alginate backbones and is thus preferred for drug delivery applications.32 Other 
strategies, which do not imply the rupture of carbon-carbon bonds in the alginate backbone, 
include sulfation,33 activation of the hydroxyl groups as cyanate esters followed by coupling with 
amine derivatives to produce isourea linkage,34 or derivatization with succinic anhydride to insert 
new carboxylic groups on the alginate backbone for subsequent carbodiimide-based coupling.16 
In order to maintain all carboxyl groups of Na-alg available for ionic cross-linking, we focused 
on the modification of the hydroxyl groups of the alginate backbone.35 Due to 1,3-diaxial 
interactions, only the hydroxyl moieties in C3 position of the mannuronic residues and C2 
position of the guluronic residues are expected to be derivatized.36  
Na-alg (Kelton HV) was first converted into tetrabutyl ammonium (TBA)-alg to increase 
solubility in DMSO for further chemical derivatization (Scheme 2). While heterogeneous 
acidification of Na-alg with ethanolic solution of HCl led to high variability in terms of viscosity 
of the solution of final TBA-alg (Table 1, entries 1 and 2), treatment with an ethanolic solution 
of formic acid (20%), followed by addition of TBAOH, afforded TBA-alg with high 
reproducibility of its composition and viscosity in 2 wt % solution.37-39 In this transformation, it 
was established that the conversion of Na-alg into alginic acid should be performed at 0°C 
(Table 1, entries 3 and 4) as higher temperature of the reaction mixture led to molar mass 
reduction of the polymer, indicated by lower viscosity of the solution. In addition, the pH should 
be strictly adjusted to 7 during the addition of TBAOH to avoid alginate backbone degradation 
(Table 1, entries 3 and 5). Finally, these optimized conditions allowed scaling-up the protocol to 
5 g of starting Na-alg (Table 1, entry 6). 
Table 1. Optimization of the production of TBA-alg. 
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Entry Acidb T 
(°C) 
pH Viscosityc 
(mPa.s) 
1a HCl 0°C nd 133 
2a HCl 0°C nd 87 
3a HCO2H 0°C 7 156 
4a HCO2H 24°C 7 77 
5a HCO2H 0°C 9 54 
6d HCO2H 0°C 7 174 
aReaction was performed on 1 g of Na-alg. b20 % solution in EtOH. cViscosity of the solution 
containing 2 wt % of TBA-alg (solvent: deionized water; measured at 22°C). dReaction was 
performed on 5 g of Na-alg. 
Conjugation of PEG derivatives to the alginate backbone was achieved by activation of the 
hydroxyl moieties in the presence of  equimolar amount of 1,1'-carbodiimidazole (CDI)40 
followed by coupling with the end amino groups of PEG I and PEG II to afford PEG-
functionalized alginates with a carbamate linkage as grafting unit. While running the two steps 
successively in DMSO was attempted, higher reproducibility was achieved by precipitating the 
intermediate activated imidazolide from DMSO and performing the second step in aqueous 
solution. Carbamate formation required a low amount of PEG derivatives (0.2 equiv) and was 
completed within 2 h at room temperature. Increasing the proportion of heterobifunctionalized 
PEG compounds did not lead to a higher degree of grafting to the alginate backbone. Other 
activating agents such as N,N'-disuccinimidyl carbonate, p-nitro-phenylchloroformate and 
isocyanates were investigated but did not lead to any detectable grafting of PEG derivatives. The 
isolation and purification of PEG-functionalized Na-alg with suitable physical properties for MS 
formation involved the addition of 0.05 M NaOH to the reaction mixture to regenerate the 
sodium salt, followed by successive dialysis cycles against water, in the presence of TCEP to 
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prevent disulfide bond and disulfide cluster formation, and final neutralization by addition of 
aqueous NaHCO3. 
Scheme 2. Functionalization of Na-alg by formation of carbamate linkage. 
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The expected chemical structures of PEG-grafted alginates were confirmed by NMR 
spectroscopy. The 1H-NMR spectrum (supporting information S8) of Alg-PEG-a I displayed 
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characteristic signals (triplets) at 3.42, 3.23, 2.98 and 2.71 ppm for CH2 linked to carbamate, 
amide from the NH and C(O) termini and SH, respectively. A large peak at 3.80-3.63 ppm 
corresponds to the other PEG CH2 groups. In addition, PEG grafted alginates were analyzed by 
Diffusion Ordered Spectroscopy (DOSY), which confirmed that the PEG derivatives were 
covalently conjugated to the alginate backbone (supporting information S9). The 1H-NMR 
spectrum (supporting information S10) of Alg-PEG-a II displayed broad peaks at 2.27-2.18 and 
1.54 ppm corresponding to CH2 groups of the 1,2-dithiolane moiety.  
We previously established the viscosity of the polymer solution at defined concentration and 
known degree of grafting as a key parameter, which directly influences the quality and physical 
properties of the resulting MS.12,16  Appropriate data is presented for Alg-PEG derivatives in 
Table 2. While the concentration and the degree of grafting directly correspond to the number of 
possible ionic and covalent crosslinks, the viscosity is a crucial parameter for the encapsulator 
settings. It depends on the molar mass and the type of the alginate backbone, the degree of 
grafting, the length and the type of the grafted PEG chain, the solvent compositing, as well as the 
concentration and temperature of the solution. 
We observed higher degree of grafting upon functionalization with PEG-b but this was not 
accompanied by higher viscosity of the solution.  Different solution behavior at different degrees 
of branching and length of the side chain branches could be hypothesized causing differences in 
the viscosity. 
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Table 2. Characteristics for Alg-PEG derivatives. 
Product Viscosity (mPa.s)a Degree of graftingb (%) 
 3 wt %  4 wt %   
Alg-PEG-a I 209 - 5.2 
Alg-PEG-a II 161 - 6.7 
Alg-PEG-b I - 53 13.0 
Alg-PEG-b II - 161 21.0 
Na-alg 245 586 - 
aViscosity of the solution containing a defined concentration of Alg-PEG polymer (solvent: 
deionized water; measured at 22°C).  bMeasured by 1H-NMR 
Microsphere formation and characterization. Solutions of the Alg-PEG derivatives in MOPS 
(10 mM, pH = 7.4), at the concentration indicated in Table 2, were extruded into a gelation bath 
containing CaCl2 as ionic crosslinker to produce MS which were assessed for their size, 
mechanical resistance to compression and elasticity/shape recovery. For the derivatives 
containing end 1,2-dithiolane moieties, dithiothreitol (DTT) (0.5 eq relative to the PEG chains) 
was added to the initial solution of polymer to favor disulfide clusters formation. For 
comparison, MS were formed under similar conditions with pure Na-alg at initial concentrations 
of 3 and 4 wt %.  As presented in Table 3, the MS diameter did not show significant change 
when comparing the data obtained at the day of the production and after storage for 7 days in the 
gelation bath, For PEG-a and PEG-b, the functionalization with 1,2-dithiolanes (II) led to the 
formation of smaller beads. When submitted to uniaxial compression 4 days after their 
formation, all MS presented the same general profile characterized by minimal mechanical 
resistance until 50% compression of their initial diameter, followed by slight increase until 70% 
and exponential evolution until 90% compression. When compressed to 90% of their initial 
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diameter, Alg-PEG-a MS demonstrated, at 3 wt %, higher mechanical resistance than pure Ca-
alg MS, while the values for Alg-PEG-b MS were even lower than for pure Ca-alg MS at 4 wt%. 
Table 3. Size of MS and mechanical resistance to uniaxial compression of MS 
Polymer 
Concentrationa 
(wt %) 
d1b (?m) d7b (?m) Mechanical 
resistancec (N/mm3) 
Alg-PEG-a I 3 934 ± 101 913 ± 105 3.0 
Alg-PEG-a II 3 667 ± 98 642 ± 84 5.0 
Na-alg 3 1048 ± 93 1028 ± 77 2.4 
Alg-PEG-b I 4 1335 ± 118 1263 ± 122 1.2 
Alg-PEG-b II 4 760 ± 83 715 ± 76 2.0 
Na-alg 4 997 ± 127 986 ± 81 2.6 
a
 in MOPS (10 mM, pH = 7.4). bMeasured with an Olympus AX70 microscope equipped with an 
Olympus DP70 color digital camera. cMechanical resistance to uniaxial compression to 90% of 
the initial MS diameter, volume-normalized. 
The mechanical properties of the MS were further assessed by evaluation of their shape recovery 
performance upon repeated compression to 90% of the initial MS diameter (Figure 1). Visible 
become the shortcomings of the physical properties of Ca-alg MS, their limited mechanical 
resistance and poor shape recovery, as previously reported.13 The performance of the MS was 
significantly better for PEG-grafted alginates than for pure Na-alg, which is attributed to 
covalent crosslinking. At 3 wt % polymer concentration, Alg-PEG-a I MS demonstrated almost 
40 % shape recovery after 10 compressions while Ca-alg MS showed complete loss of shape 
recovery after 5 compressions. For longer PEG chains grafted to the backbone, the recovery 
performance of alg-PEG-b I MS was higher than 50% even after 10 compressions. The polymers 
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with end thiol functionalities produce MS with better recovery than the polymers with 1,2-
dithiolane moieties (alg-PEG I vs alg-PEG II systems in Figure 1A and 1B). 
Figure 1. Elasticity/shape recovery upon coaxial compression 
 
(A) Resistance to 10 successive compressions to 90% of Alg-PEG-a I MS (3 wt %), Alg-PEG-a 
II MS (3 wt %) and Ca-alg MS (3 wt %); (B) resistance to 10 successive compressions of Alg-
PEG-b I MS (4 wt %), Alg-PEG-b II MS (4 wt %) and Ca-alg MS (4 wt %). 
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Cell microencapsulation. Considering their higher mechanical resistance to compression (Table 
3), both Alg-PEG-a I and Alg-PEG-a II were considered to evaluate the feasibility of cell 
microencapsulation, using the mouse insulinoma cell line MIN6 as model cells. Encapsulation of 
MIN6 cells was performed under physiological conditions by extrusion in a gelation bath 
containing CaCl2. This one-step process delivered MS of average diameters between 500 and 
600 ?m. Homogeneous cells distribution within both MS types was observed and no free cells 
were detected in the surrounding medium. The cell viability, assessed by FDA/PI staining at 3 
and 15 days after encapsulation reached almost 80 % with both polymers and was constant over 
time (Figure 2). However, the nature of the terminal functionality of the PEG chains influenced 
the integrity of the microspheres network over time. During 15 days, the integrity of Alg-PEG-a 
I MS was evidenced as no free cells were identified in the culture medium. The MS from Alg-
PEG-a II appeared degraded over time and out-diffusion of cells was identified from day 10. By 
light microscopy, the MS showed a lucent appearance. This observation indicates that covalent 
cross-linking resulting from 1,2-dithiolane moieties is reversible under the physiological 
conditions used for cell culture. Changing the functionalities installed on the PEG chain for 
covalent cross-linking seems to have the potential to modulate the stability of the resulting MS 
so that the functionalization of the alginate derivative can be selected depending on the type of 
intended application. 
Figure 2. MIN6 cells microencapsulated in Alg-PEG-a I and Alg-PEG-a II MS. 
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Photographs are from day 3 and day 15 after microencapsulation and culture. For each polymer, 
upper panel: light microscopy, middle panel: staining of live cells with fluorescein diacetate 
(FDA, green), lower panel: staining of dead cells with propidium iodide (PI, red). Insert at the 
bottom: illustrates the loss of integrity of Alg-PEG-a II MS from day 10. 
Free non-encapsulated MIN6 cells and microencapsulated MIN6 cells were subjected to a 
glucose-stimulated insulin release assay under static conditions, for both MS at day 3 and day 10 
after microencapsulation (Figure 3). Stimulation was done at a glucose concentration of 16.7 
mM, and the fold increase of insulin release was expressed with respect to the insulin release at 
basal glucose concentration of 2.8 mM, which was set as 1. The assay outcome was the same for 
free MIN6 cells and microencapsulated MIN6 cells, using either Alg-PEG-a I or Alg-PEG-a II 
MS, showing that the insulin-secreting capacity is maintained upon microencapsulation. 
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Figure 3. Glucose-stimulated insulin release for non-encapsulated MIN6 cells (Free) and MIN6 
cells microencapsulated in MS of Alg-PEG-a I and Alg-PEG-a II. 
 
Finally, the suitability of Alg-PEG-a I and Alg-PEG-a II systems for cell transplantation was 
assessed by the transplantation of empty MS formed from both systems in immune-competent 
mice, with a follow-up period of 30 days. Upon sacrifice of the mice, the MS were 
macroscopically inspected and retrieved (supporting information S11, Figure S1).  At 
macroscopic inspection MS were visible. There were no signs of inflammation, neither 
connective tissue formation nor fibrosis, indicating no major host incompatibility for MS from 
both PEG grafted alginate derivatives. 
CONCLUSION 
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A synthetic route was developed to functionalize the hydroxyl groups of the biopolymer sodium 
alginate with heterobifunctional PEG derivatives containing end thiol (I) or 1,2-dithiolane (II) 
functionalities for covalent cross-linking. Alg-PEG derivatives are obtained by activation of 
hydroxyl moieties in the form of imidazolide, followed by formation of covalent carbamate 
linkage with heterocheletic PEG derivatives. In comparison to pure Ca-alg MS, the MS obtained 
from Alg-PEG derivatives presented improved mechanical properties, in particular for shape 
recovery following multiple compressions. The nature of the end functionality of the grafted 
PEG chains has a direct impact on the physical properties of the resulting MS, and also 
influences their stability in physiological environment. For the same encapsulator settings, Alg-
PEG I derivatives provided larger MS with superior elasticity performance than Alg-PEG II 
polymers. The potential of these materials for cell microencapsulation was demonstrated using 
MIN6 cells which showed good viability and insulin production capacity over two weeks. 
Interestingly, MS formed by combined ionic gelation and disulfide bride covalent cross-linking 
present higher durability in culture medium than MS formed by combined ionic gelation and 
disulfide clusters. The chemical composition of the PEG grafting unit can thus be adjusted to 
provide long term stability or degradation of the MS over time, depending on the targeted 
application. Noteworthy, MS are obtained from a single polymeric component, and using a one-
step protocol which is not detrimental to cell survival and functionality. Preliminary in vivo 
studies gave evidence for the good bioacceptance of Alg-PEG-a I and Alg-PEG-a II MS, 
extending the panel of polymeric materials for cell microencapsulation. The chemical pathways 
disclosed herein provide a new basis for the covalent functionalization of the alginate backbone 
which can be further applied to the conjugation of bioactive molecules for controlled delivery at 
the transplantation site. 
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Alg, alginate; Boc, tert-butyloxycarbonyl; CDI, carbodiimidazole; DCM, dichloromethane; 
DMEM, Dulbecco Modified Eagle's Medium; DMF, N,N-dimethyl formamide; DMSO, 
dimethyl sulfoxide; DTT, dithiothreitol; EDCI, 1-ethyl-3-[3-
(dimethylamino)propyl]carbodiimide; FCC, flash column chromatography, FDA, fluorescein 
diacetate; MOPS, 3-(N-morpholino) ethanesulfonic acid; MS, microsphere; PE, petroleum ether; 
PEG, poly(ethylene glycol); PI, propidium iodide; rt, room temperature; TBA, tert-butyl 
ammonium; TCEP, tris(2-carboxyethyl)phosphine; THF, tetrahydrofuran. 
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